Givinostat
Brand names: Duvyzat · Active ingredient: Givinostat
In short: DUVYZAT is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 6 years of age and older.
What is Givinostat used for?
DUVYZAT is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 6 years of age and older.
Givinostat dosage
Obtain and evaluate baseline platelet counts and triglycerides prior to initiation of DUVYZAT . Do not initiate DUVYZAT in patients with a platelet count less than 150 x 109/L. Monitor platelet counts and triglycerides as recommended during treatment to determine if dosage modifications are needed .
In addition, in patients with underlying cardiac disease or taking concomitant medications that cause QT prolongation, obtain ECGs when initiating treatment with DUVYZAT, during concomitant use, and as clinically indicated [see Dosage and Administration (2.3), Warnings and Precautions (5.4), and Drug Interactions (7.2)].
The recommended dosage of DUVYZAT is based on body weight and administered orally twice daily with food .
WeightBased on actual body weight | Dosage | Oral Suspension Volume
10 kg to less than 20 kg | 22.2 mg twice daily | 2.5 mL twice daily
20 kg to less than 40 kg | 31 mg twice daily | 3.5 mL twice daily
40 kg to less than 60 kg | 44.3 mg twice daily | 5 mL twice daily
60 kg or more | 53.2 mg twice daily | 6 mL twice daily
Decrease in Platelets, Diarrhea, Increase in Triglycerides
DUVYZAT may cause adverse reactions , which may necessitate a dosage modification if the following occur:
Platelet count <150 x 109/L verified in two assessments one week apartor
Moderate or severe diarrhea or
Fasting triglycerides >300 mg/dL verified by two assessments one week apart
Based on the severity of these adverse reactions, treatment interruption prior to dosage modification should be considered.
First Dosage ModificationIf the adverse reaction(s) persist after the first dosage modification, proceed to the second dosage modification. | Second Dosage ModificationIf the adverse reaction(s) persist after the second dosage modification, DUVYZAT should be discontinued.
WeightBased on actual body weight | Dosage | Oral Suspension Volume | Dosage | Oral Suspension Volume
10 kg to less than 20 kg | 17.7 mg twice daily | 2 mL twice daily | 13.3 mg twice daily | 1.5 mL twice daily
20 kg to less than 40 kg | 22.2 mg twice daily | 2.5 mL twice daily | 17.7 mg twice daily | 2 mL twice daily
40 kg to less than 60 kg | 31 mg twice daily | 3.5 mL twice daily | 26.6 mg twice daily | 3 mL twice daily
60 kg or more | 39.9 mg twice daily | 4.5 mL twice daily | 35.4 mg twice daily | 4 mL twice daily
QTc Interval Prolongation
Withhold DUVYZAT if the QTc interval is > 500 ms or the change from baseline is > 60 ms .
See the Instructions for Use for further details.
Before use, shake the DUVYZAT suspension for at least 30 seconds by inverting the bottle by 180°.
Visually verify the homogeneity of the suspension.
Using a graduated oral syringe, measure the appropriate volume of suspension corresponding to the prescribed dose of DUVYZAT. …
How to take Givinostat — instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (Medication Guide and Instructions for Use).
Administration Instructions
Instruct patients or caregivers to :
Shake DUVYZAT oral suspension well before measuring out each dose.
Administer using the provided graduated oral syringe to measure the appropriate volume of suspension corresponding to the prescribed dose for the patient.
Take DUVYZAT with food.
Discard any unused DUVYZAT oral suspension remaining after 60 days of first opening the bottle.
Hematological Changes
Inform patients and/or caregivers that DUVYZAT can cause hematological changes including a decrease in platelet counts (thrombocytopenia), anemia, and a decrease in neutrophils (neutropenia) . Advise patients to notify their healthcare provider if they have any signs or symptoms of these adverse reactions (e.g., easy bruising, excessive bleeding from cuts, blood in the stool, fatigue). Instruct patients to adhere to the testing recommended to monitor for these adverse reactions. Inform patients that their dosage may need to be changed or their treatment may need to be stopped depending on the results of their test for platelet counts. …
Warnings & precautions
Do not take this medicine if: None.
DUVYZAT can cause dose-related thrombocytopenia and other signs of myelosuppression, including decreased hemoglobin and neutropenia.
In Study 1 , thrombocytopenia occurred in 33% of patients treated with DUVYZAT compared to no patients on placebo. The maximum decrease in platelets occurred within the first 2 months of therapy and remained low throughout the course of therapy. In a few patients, thrombocytopenia was associated with bleeding events including epistaxis, hematoma or contusions. Low platelet counts resulted in DUVYZAT dose reduction in 28% of patients. Patients with baseline platelet counts below the lower limit of normal were excluded from the study.
Decreased hemoglobin and decreased neutrophils were also observed in patients treated with DUVYZAT compared to placebo.
Monitor blood counts every 2 weeks for the first 2 months of treatment, at month 3, and then every 3 months thereafter. Modify the dosage of DUVYZAT for confirmed thrombocytopenia . Treatment should be permanently discontinued if the abnormalities worsen despite dose modification. If a patient develops signs or symptoms of thrombocytopenia, obtain a platelet count as soon as possible, and hold dosing until platelet count is confirmed.
DUVYZAT can cause elevations in triglycerides. In Study 1 , hypertriglyceridemia occurred in 23% of patients treated with DUVYZAT (one of whom had familial hypertriglyceridemia) compared to 7% of patients on placebo. High triglycerides (i.e., levels greater than 300 mg/dL) resulted in discontinuation and led to dosage modification in 2% and 8%, respectively, of patients treated with DUVYZAT.
Monitor triglycerides at 1 month, 3 months, 6 months, and then every 6 months thereafter. Modify the dosage if fasting triglycerides are verified > 300 mg/dL . …
Givinostat side effects
The following clinically significant adverse reactions are described below and elsewhere in the labeling:
Hematological Changes
Increased Triglycerides
Gastrointestinal Disturbances
QTc Prolongation
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
In controlled and uncontrolled trials in patients with confirmed DMD, 222 male patients aged 6 years and older were treated with DUVYZAT, including 210 patients treated for ≥ 6 months, 187 patients for ≥ 12 months, and 105 patients for ≥ 24 months.
The safety profile of DUVYZAT is based on a double-blind, placebo-controlled, 18-month study in a total of 179 ambulant DMD patients aged 6 years or older on concomitant steroid treatment (Study 1) . The dosage in Study 1 was weight-based . Patients were excluded from the study if they had the following abnormalities at the screening visit: platelet, white blood cell, or hemoglobin counts less than the lower limit of normal, triglycerides > 300 mg/dL (3.42 mmol/L) in fasting condition, or had a baseline-corrected QT interval, Fridericia’s correction (QTcF) of > 450 msec (mean of 3 consecutive readings 5 minutes apart) or a history of additional risk factors for torsades de pointes (e.g., heart failure, hypokalemia, or family history of long QT syndrome). …
Drug interactions
CYP3A4 Sensitive Substrates
Givinostat is a weak intestinal CYP3A4 inhibitor . Closely monitor when DUVYZAT is used in combination with orally administered CYP3A4 sensitive substrates for which a small change in substrate plasma concentration may lead to serious toxicities.
OCT2 Sensitive Substrates
Givinostat is a weak inhibitor of the renal uptake transporter OCT2 . Closely monitor when DUVYZAT is used in combination with drugs known as a sensitive substrate of the OCT2 transporter for which a small change in substrate plasma concentration may lead to serious toxicities.
Drugs that Prolong the QTc Interval
Avoid concomitant use of DUVYZAT with other product(s) with a known potential to prolong the QTc interval. If concomitant use cannot be avoided, obtain ECGs when initiating, during concomitant use, and as clinically indicated . Withhold DUVYZAT if the QTc interval is > 500 ms or the change from baseline is > 60 ms .
DUVYZAT causes QTc interval prolongation . Concomitant use of DUVYZAT with other products that prolong the QTc interval may result in a greater increase in the QTc interval and adverse reactions associated with QTc interval prolongation, including Torsade de pointes, other serious arrythmias, and sudden death .
About this medicine
DUVYZAT (givinostat) oral suspension contains givinostat hydrochloride monohydrate, a histone deacetylase inhibitor. Givinostat hydrochloride monohydrate is designated chemically as: [6-(diethylaminomethyl)naphthalen-2-yl]methyl[4(hydroxycarbamoyl) phenyl] carbamate hydrochloride monohydrate. The molecular formula is C24H27N3O4•HCl•H2O and the molecular weight is 475.97 g/mol. Its structural formula is:
Givinostat hydrochloride monohydrate is a white to off-white, non-hygroscopic, crystalline powder that is very slightly to slightly soluble in aqueous media and slightly soluble in ethanol.
DUVYZAT contains givinostat 8.86 mg/mL (equivalent to givinostat hydrochloride monohydrate 10 mg/mL) and the following inactive ingredients: cream flavor, glycerin, non-crystallizing sorbitol solution, peach flavor, polysorbate 20, purified water, saccharin sodium, sodium benzoate, sodium hydroxide, tartaric acid, and tragacanth.
How it works: DUVYZAT is a histone deacetylase inhibitor. The precise mechanism by which DUVYZAT exerts its effect in patients with DMD is unknown. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 1a28a3db-7880-4ac2-a2f2-2b4e362aafb6. Read the full official label on DailyMed.